TY - JOUR T1 - Tiotropium add-on therapy reduces seasonal peaks of asthma worsening in adults with symptomatic severe asthma JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.00964-2019 VL - 55 IS - 1 SP - 1900964 AU - J. Mark FitzGerald AU - Roland Buhl AU - Thomas B. Casale AU - Branko Jugovic AU - Liliana Zaremba-Pechmann AU - David M.G. Halpin Y1 - 2020/01/01 UR - http://erj.ersjournals.com/content/55/1/1900964.abstract N2 - Despite the use of preferred controller therapies (including inhaled corticosteroids (ICS) with or without additional long-acting β2-agonists (LABAs)), a large proportion of patients with asthma have poor disease control, leaving them at risk of recurring symptoms and episodes of asthma exacerbations and worsening [1, 2]. Such problems can be triggered by many different environmental factors including pollutants, respiratory infections or allergens [3]. They may occur sporadically, but are often determined by the seasons, mirroring seasonal patterns of allergen exposure and prevalence of respiratory viral infection [3, 4].In adults with symptomatic severe asthma despite inhaled corticosteroid/long-acting β2-agonist therapy, tiotropium add-on therapy reduces seasonal peaks of asthma worsening, providing a year-round benefit http://bit.ly/2m4LGuHThe authors take full responsibility for the scope, direction, content and editorial decisions relating to the manuscript, were involved at all stages of development and have approved the submitted manuscript. Medical writing assistance, in the form of the preparation and revision of the draft manuscript, was supported financially by Boehringer Ingelheim and provided by Rosie Robson of MediTech Media (Manchester, UK), under the authors’ conceptual direction and based on feedback from the authors. ER -